Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)

Diagnostik, Therapie und Nachsorge des Vaginalkarzinoms und seiner Vorstufen. Leitlinie der DGGG und der DKG (S2k-Level, AWMF Registry No. 032/042, Oktober 2018)

Authors

Hans-Georg Schnürch¹, Sven Ackermann², Celine D. Alt-Radtke³, Lukas Angleitner⁴, Jana Barinoff⁵, Matthias W. Beckmann⁶, Carsten Böing⁷, Christian Dannecker⁸, Tanja Fehm⁹, Rüdiger Gaase¹⁰, Paul Gass⁶, Marion Gebhardt¹¹, Friederike Giesecking¹², Andreas Günthert¹³, Carolin C. Hack⁶, Peer Hantschmann¹⁴, Lars Christian Horn¹⁵, Martin C. Koch⁶, Anne Letsch¹⁶, Peter Mallmann¹⁷, Bernhard Mangold¹⁸, Simone Marnitz¹⁹, Grit Mehlhorn²⁰, Kerstin Paradies²¹, Michael J. Reinhardt²², Reina Tholen²³, Uwe Torsten²⁴, Wolfgang Weikel²⁵, Linn Wölber²⁶, Monika Hampl⁹

Affiliations

- 1 Ehem. Frauenklinik Lukaskrankenhaus, Neuss, Germany
- 2 Frauenklinik, Klinikum Darmstadt, Darmstadt, Germany
- 3 Institut für Diagnostische und Interventionelle Radiologie, Universität Düsseldorf, Düsseldorf, Germany
- 4 Frauenklinik, Kepler-Universitätsklinikum Linz, Linz, Austria
- 5 St.-Gertrauden-Krankenhaus GmbH Berlin, Berlin, Germany
- 6 Frauenklinik, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg; Comprehensive Cancer Center (CCC) Erlangen-EMN, Erlangen, Germany
- 7 Katholisches Klinikum Oberhausen, Frauenklinik St. Clemens-Hospital, Oberhausen, Germany
- 8 Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universität München, Campus Großhadern, München, Germany
- 9 Klinik für Frauenheilkunde und Geburtshilfe, Universität Düsseldorf, Düsseldorf, Germany
- 10 Gemeinschaftspraxis für Frauenheilkunde Gaase+Hugger, Worms, Germany
- 11 Frauenselbsthilfe nach Krebs, Erlangen, Germany
- 12 Dysplasiesprechstunde/Gynäkologisches Laserzentrum in der Frauenarztpraxis Heussweg, Hamburg, Germany
- 13 Gyn-Zentrum für Frauengesundheit, Luzern, Switzerland
- 14 Abteilung Gynäkologie und Geburtshilfe, Kreiskliniken Altötting – Burghausen, Altötting, Germany
- 15 Institut für Pathologie, Universitätsklinikums Leipzig, Leipzig, Germany
- 16 Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charité Berlin, Berlin, Germany
- 17 Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universität Köln, Köln, Germany

- 18 Zyto-Labor Ludwigsburg, Ludwigsburg, Germany
- 19 Klinik für Radioonkologie, CyberKnife- und Strahlentherapie, Uniklinik Köln, Köln, Germany
- 20 Frauenarztpraxis Erlangen, Erlangen, Germany
- 21 Konferenz Onkologischer Kranken- und Kinderkrankspflege, Berlin, Germany
- 22 Klinik für Nuklearmedizin, Pius-Hospital Oldenburg, Oldenburg, Germany
- 23 Deutscher Verband für Physiotherapie, Köln, Germany
- 24 Klinik für Gynäkologie und Zentrum für Beckenboden-erkrankungen, Vivantes Klinikum Neukölln, Berlin, Germany
- 25 Klinik für Gynäkologie und gynäkologische Onkologie, Universitätsfrauenklinik Mainz, Mainz, Germany
- 26 Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Key words

vaginal cancer, VaIN, sentinel lymph node biopsy

Schlüsselwörter

Vaginalkarzinom, VaIN, Sentinel-Biopsie

received 13. 5. 2019

accepted 13. 5. 2019

Bibliography

DOI <https://doi.org/10.1055/a-0919-4959>

Published online 16. 7. 2019 | Geburtsh Frauenheilk 2019; 79: 1060–1078 © Georg Thieme Verlag KG Stuttgart · New York | ISSN 0016-5751

Correspondence

Prof. Dr. Hans-Georg Schnürch
Im Hunengraben 9, 41564 Kaarst, Germany
hgschnuerch@gmail.com

ABSTRACT

Purpose This is an official guideline, published and coordinated by the Gynecological Oncology Working Group (AGO) of the German Cancer Society (DKG) and the German Society for Gynecology and Obstetrics (DGGG). Vaginal cancers are rare tumors, which is why there is very little evidence on these tumors. Knowledge about the optimal clinical management is limited. This first German S2k guideline on vaginal cancer has aimed to compile the most current expert knowledge and offer new recommendations on the appropriate treatment as well as providing pointers about individually adapted therapies with lower morbidity rates than were previously generally available. The purpose of this guideline is also to set up a register to record data on treatment data and the course of disease as a means of obtaining evidence in future.

Methods The present S2k guideline was developed by members of the Vulvar und Vaginal Tumors Commission of the AGO in an independently moderated, structured, formal consensus process and the contents were agreed with the mandate holders of the participating scientific societies and organizations.

Recommendations To optimize the daily care of patients with vaginal cancer: 1. Monitor the spread pattern; 2. Follow the step-by-step diagnostic workup based on initial stage at detection; 3. As part of individualized clinical therapeutic management of vaginal cancer, follow the sentinel lymph

node protocol described here, where possible; 4. Participate in the register study on vaginal cancer.

ZUSAMMENFASSUNG

Ziel Offizielle Leitlinie, publiziert und koordiniert von der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) in der Deutschen Krebsgesellschaft (DKG) und der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Vaginalkarzinome gehören zu den seltenen Tumoren, dadurch fehlen bisher Evidenzen. Kenntnisse über das optimale klinische Management sind gering. Diese erste deutsche S2k-Leitlinie zum Vaginalkarzinom soll das aktuelle Expertenwissen zusammentragen und neue Behandlungsempfehlungen anbieten, um eine individuell angepasste Therapie mit geringerer Morbidität als bisher zu ermöglichen. Zur zukünftigen Gewinnung von Evidenzen soll eine Registerstelle für die Behandlungsdaten und Krankheitsverläufe eingerichtet werden.

Methoden Die vorliegende S2k-Leitlinie wurde von den Mitgliedern der Kommission Vulva- und Vaginaltumoren der AGO entworfen, in einem unabhängig moderierten formalen Konsensusverfahren strukturiert entwickelt und mit den Mandatsträgern der beteiligten Fachgesellschaften und Organisationen abgestimmt.

Empfehlungen Für die tägliche Optimierung der Versorgung von Patientinnen mit Vaginalkarzinom gilt: 1. Beachtung des Ausbreitungsmusters. 2. Einhaltung der abgestuften Diagnostik in Abhängigkeit vom Ausgangsstadium. 3. Wenn möglich Einsatz des Sentinel-Verfahrens im Rahmen eines individualisierten klinisch-therapeutischen Managements der Vaginalkarzinome. 4. Teilnahme an der Registerstudie zum Vaginalkarzinom.

I Guideline Information

Guidelines program of the DGGG, OEGGG and SGGG

For information on the guidelines program, please refer to the end of the guideline.

Citation format

Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No.032/042, October 2018). Geburtsh Frauenheilk 2019; 79: 1060–1078

Guideline documents

The complete long version in German, the short version and a German-language PDF slide version for PowerPoint presentations are available on the homepage of the AWMF: <https://www.awmf.org/leitlinien/detail/II/032-042.html>

Numbering

This text version of the guideline is a concise abridged version which has omitted generally applicable chapters (12 Supportive Therapy, 13 Psycho-oncology and Quality of Life, 14 Rehabilitation, 15 Integrative Medicine, 18 Palliative Medical Support). The numbering of the chapters after “IV Guideline” and the numbering of the recommendations and statements in this short version corresponds to the numbering used in the long version, despite the obvious gaps in numbering. This was done to make it easier to find the text in the long version if further information is desired.

Guideline group

The members of the guideline group are listed under “Authors”. The group is composed of authors and mandate holders. The latter are representatives of the medical societies, working groups, organizations, and associations who stated their interest in being involved in the compilation of the guideline text and participated in the consensus conference. The authors and mandate holders and their functions are listed in ► Table 1.

► **Table 1** Guideline authors and mandate holders (listed alphabetically).

Author, mandate holder	Function*	Group, body
Ackermann, PD Dr. med. Sven	A	German Society of Gynecology and Obstetrics [Deutsche Gesellschaft für Gynäkologie und Geburtshilfe] (DGGG), German Cancer Society [Deutsche Krebsgesellschaft] (DKG), Gynecological Oncology Working Group [Arbeitsgemeinschaft Gynäkologische Onkologie] (AGO)
Alt-Radtke, Dr. med. Celine Desirée	A, M	German Roentgen Society [Deutsche Röntgengesellschaft] (DRG), Uroradiology Working Group [AG Uroradiologie]
Angleitner, Prof. Dr. Lukas	M	Austrian Society of Gynecology and Obstetrics [Österreichische Gesellschaft für Gynäkologie und Geburtshilfe] (OEGGG)
Barinoff, Dr. med. Jana	A	DGGG, DKG, AGO
Beckmann, Prof. Dr. med. Matthias W.	A	DGGG, DKG, German Cancer Aid [Deutsche Krebshilfe] (DKH), German Society for Senology [Deutsche Gesellschaft für Senologie] (DGS), AGO, Comprehensive Cancer Center Erlangen EMN (CCC ER-EMN)
Böing, Dr. med. Carsten	A	DGGG, DKG, AGO
Dannecker, Prof. Dr. med. Christian	A	DGGG, DKG, AGO
Fehm, Prof. Dr. med. Tanja	M	AGO Executive Board
Gaase, Dr. med. Rüdiger	M	Professional Association of Gynecologists [Berufsverband der Frauenärzte e. V.] (BVF)
Gaß, Dr. med. Paul	A	DGGG-Leitliniensekretariat
Gebhardt, Marion	M	Federal Association of Women's Self-help Groups After Cancer [Bundesverband Frauenselbsthilfe nach Krebs e. V.] (FSH)
Giesecking, Dr. med. Friederike	A, M	DGGG, DKG, AGO, Cervical Pathology and Colposcopy Working Group [AG Cervix-Pathologie und Colposcopie] (AGCPC)
Günthert, Prof. Dr. med. Andreas	A	DGGG, DKG, AGO
Hack, PD Dr. med. Caroline C.	A, M	DGGG, DKG, AGO
Hampl, Prof. Dr. med. Monika	A, M	DGGG, DKG, AGO
Hantschmann, Dr. med. Peer	A	DGGG, DKG, AGO
Horn, Prof. Dr. med. Lars Christian	A, M	German Society of Pathology [Deutsche Gesellschaft für Pathologie] (DGP), DKG, AGO
Koch, Dr. med. Martin C.	A	DGGG, DKG, AGO
Letsch, Dr. med. Anne	A, M	German Society for Hematology and Medical Oncology [Deutsche Gesellschaft für Hämatologie und medizinische Onkologie] (DGHO), German Society for Palliative Medicine [Deutsche Gesellschaft für Palliativmedizin] (DGPM)
Mallmann, Prof. Dr. med. Peter	A, M	DGGG, DKG, AGO
Mangold, Dr. med. Bernhard	A, M	German Society for Cytology [Deutsche Gesellschaft für Zytologie] (DGZ)
Marnitz, Prof. Dr. med. Simone	A, M	German Society for Radio-oncology [Deutsche Gesellschaft für Radioonkologie] (DEGRO), DKG, AGO
Mehlhorn, PD Dr. med. Grit	A	DGGG, DKG, AGO
Paradies, Kerstin	M	Conference for Oncological Nursing Care and Nursing Care of Children [Konferenz onkologischer Kranken- und Kinderkrankenpflege e. V.] (KOK)
Reinhardt, Prof. Dr. med. Michael J.	M	German Society of Nuclear Medicine [Deutsche Gesellschaft für Nuklearmedizin e. V.] (DGN)
Schnürch, Prof. Dr. med. Hans-Georg	A, M	DGGG, DKG, AGO
Tholen, Reina	M	German Association for Physiotherapy [Deutscher Verband für Physiotherapie]
Torsten, PD Dr. med. Uwe	A	DGGG, DKG, AGO
Weikel, Prof. Dr. med. Wolfgang	A	DGGG, DKG, AGO
Wetzig, PD Dr. med. Tino	M	German Dermatological Society [Deutsche Dermatologische Gesellschaft] (DDG)
Wölber, Prof. Dr. med. Linn	A	DGGG, DKG, AGO
Zraik, Dr. med. Isabella	M	German Society for Urology [Deutsche Gesellschaft für Urologie] (DGU)

* A = author, M = mandate holder

Dr. M. Nothacker (an AWMF-certified guidelines advisor/moderator) kindly agreed to moderate the guideline. Dr. P. Gaß (DGGG Guidelines Office, Erlangen) contributed substantially to the compilation of the long and short versions of this guideline.

Abbreviations

AG	working group [Arbeitsgemeinschaft]
AG-CPC	Cervical Pathology and Colposcopy Working Group [Arbeitsgemeinschaft für Cervixpathologie und Colposkopie]
AGO	Gynecological Oncology Working Group [Arbeitsgemeinschaft Gynäkologische Onkologie]
AWMF	Association of the Scientific Medical Societies in Germany [Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften]
CAM	complementary and alternative medicine
CCC	comprehensive cancer center
CIN	cervical intraepithelial neoplasia
CT	computed tomography
DHCD	data-sparing homogeneous cancer documentation
DGGG	German Society of Gynecology and Obstetrics [Deutsche Gesellschaft für Gynäkologie und Geburtshilfe]
DKG	German Cancer Society [Deutsche Krebsgesellschaft]
EORTC	European Organisation for Research and Treatment of Cancer
FDG-PET	fluorodeoxyglucose-positron emission tomography
FIGO	Fédération Internationale de Gynécologie et d'Obstétrique
H&E	hematoxylin and eosin
HPV	human papillomaviruses
HSIL	high-grade squamous intraepithelial lesion
LDA	lymph drainage area
LN	lymph node
LNE	lymph node excision
LN status	lymph node status
LSIL	low grade squamous intraepithelial lesion
MRI	magnetic resonance imaging
NCCAM	National Center of Complementary and Alternative Medicine
NCDB	National Cancer Data Base
OEGGG	Austrian Society of Gynecology and Obstetrics [Österreichische Gesellschaft für Gynäkologie und Geburtshilfe]
OL	Oncology Guidelines Program [Leitlinienprogramm Onkologie]
PE	biopsy [Probe-Exzision]
PET	positron emission tomography
PNI status	perineural invasion status
QI	quality indicator
QLQ	quality of life questionnaire
R1	microscopic residual disease
R2	macroscopic residual disease
RCTX	radio(chemo)therapy
SGB	(German) Social Security Statute Book [Sozialgesetzbuch]
SGGG	Swiss Society of Gynecology and Obstetrics [Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe]

SLN	sentinel lymph node
SLNB	sentinel lymph node biopsy
SPECT	single-photon emission computed tomography
TNM system	tumor-node-metastasis staging system
UICC	Union internationale contre le cancer
VaIN	vaginal intraepithelial neoplasia
VIN	vulvar intraepithelial neoplasia
V status	vessel status
WHO	World Health Organization
WLE	wide local excision

II Guideline Application

Purpose and objectives

Although vaginal cancer is a rare tumor entity, there is no summary of recent experience or list of appropriate recommendations for the medical staff treating these rare cases. This guideline completes the range of gynecological oncology guidelines of the DGGG and DKG. As radiotherapy also plays an important role in the treatment of vaginal cancer, the interdisciplinary compilation of this guideline ensures that all treatment modalities – surgery, radiotherapy and systemic therapy – were given appropriate consideration. This guideline aims to make the specialist knowledge about the diagnosis and treatment of vaginal cancer available to all treatment teams in the form of recommendations, statements and explanatory text.

Targeted areas of patient care

The guideline covers the full spectrum of diagnosis, treatment and follow-up of patients with vaginal cancer, including patients with microinvasive lesions and high-grade precursors. This guideline's area of application is cross-sectional and includes both outpatient and inpatient care. All relevant scientific medical societies, self-help groups and professional associations in Germany were therefore involved in the compilation of this guideline.

Target user groups/target audience

This S2k guideline is aimed at all physicians and healthcare professionals involved in the outpatient and/or inpatient care of patients with vaginal cancer. This guideline also aims to serve as an important source of information for affected patients and their relatives.

Adoption and period of validity

The validity of this guideline was confirmed by the executive boards of the participating medical societies, working groups, organizations and associations as well as by the executive board of the DGGG, the DGGG guidelines commission and the DKG in October 2018 and was thus confirmed in its entirety. This guideline is valid from 1 October 2018 through to 30 September 2023. Because of the contents of this guideline, this period of validity is only an estimate.

III Method

The method used to prepare this guideline was determined by the class to which this guideline was assigned. The AWMF Guidance Manual (version 1.0) has set out the respective rules and requirements for different classes of guidelines. Guidelines are differentiated into lowest (S1), intermediate (S2) and highest (S3) class. The lowest class is defined as a set of recommendations for action compiled by a non-representative group of experts. In 2004, the S2 class was divided into two subclasses: a systematic evidence-based subclass (S2e) and a structural consensus-based subclass (S2k). The highest S3 class combines both approaches.

This guideline is classified as: **S2k**

Grading of recommendations

The grading of evidence and of recommendations is not envisaged for S2k-level guidelines. The individual Statements and Recommendations are differentiated by syntax, not by symbols (► **Table 2**).

► **Table 2** Grading of recommendations.

Level of recommendation	Syntax
Strong recommendation, highly binding	must/must not
Simple recommendation, moderately binding	should/should not
Open recommendation, not binding	may/may not

Statements

Scientific statements given in this guideline which do not consist of any direct recommendations for action but are simple statements of fact are referred to as "Statements". It is **not** possible to provide any information about the grading of evidence for these Statements.

Achieving consensus and strength of consensus

As part of the structured process to achieve consensus (S2k/S3 level), authorized participants attending the consensus conference vote on draft Statements and Recommendations. This can lead to significant changes in the wording, etc. Finally, the extent of consensus is determined based on the number of participants who voted and the number of participants who voted in favor (► **Table 3**).

► **Table 3** Grading of strength of consensus.

Symbol	Strength of consensus	Extent of agreement in percent
+++	Strong consensus	> 95% of participants agree
++	Consensus	> 75–95% of participants agree
+	Majority agreement	> 50–75% of participants agree
–	No consensus	< 51% of participants agree

Expert consensus

As the name already implies, this term refers particularly to consensus decisions on Recommendations/Statements where the decision was taken without a prior systematic search of the literature (S2k) or for which evidence is lacking (S2e/S3). The term "expert consensus" (EC) used here is synonymous with terms used in other guidelines such as "good clinical practice" (GCP) or "clinical consensus point" (CCP). The strength of the recommendation is graded as previously described in the chapter "Grading of recommendations", i.e., purely semantically ("must"/"must not" or "should"/"should not" or "may"/"may not") without the use of symbols.

Quality indicator

The QI working group of the Vulva and Vagina Commission has proposed that histological confirmation of the primary vaginal cancer prior to planning therapy in a tumor conference should be the only quality indicator for this rare entity.

IV Guideline

1 Epidemiology

Vaginal cancer is a rare tumor with only around 500 new cases reported annually in Germany [1]. The majority of all invasive vaginal cancers are squamous cell carcinomas (> 95%), followed by adenocarcinomas (< 5%) and melanomas (< 1%) [2]. The majority of clear cell adenocarcinomas are associated with maternal intake of the drug diethylstilbestrol (DES) during pregnancy [3]. Vaginal metastasis and recurrence and vaginal infiltration caused by direct expansion of an adjacent malignancy of the cervix, vulva, endometrium or rectum are more common than primary vaginal cancer, and primary vaginal carcinoma must be differentiated from all of these entities.

1.1 Age distribution

In more than 50% of cases, the age at onset of primary vaginal cancer is 70 years and above. Only 15% of these carcinomas are diagnosed in patients between the ages of 20 and 49 years [4].

1.2 Survival rate

The absolute 5-year survival rate correlates with the histological subtype: it is 54% for squamous cell carcinoma, 60% for adenocarcinoma, and 13% for patients with malignant melanoma [4]. The 5-year survival rate also correlates with the tumor stage at primary diagnosis: it is 20% for stage IV.

1.3 Risk factors

Consensus-based Statement 1.S1

Expert consensus	Strength of consensus +++
The risk factors for developing vaginal cancer are similar to those for cervical cancer.	

Consensus-based Statement 1.S2	
Expert consensus	Strength of consensus +++
Infection with human high-risk papillomavirus (HR-HPV) is one of the most important risk factors.	

Consensus-based Statement 1.S3	
Expert consensus	Strength of consensus +++
Vaginal cancer has been reported to develop in up to 5 % of cases with VaIN. A VaIN 2–3/HSIL is a precancerous lesion.	

The risk factors for developing squamous cell tumors of the vagina are the same as those for cervical cancer:

- infection with high-risk human papillomavirus
- previous treatment for preinvasive or invasive HPV-induced lesions
- multiple sexual partners
- early age at first intercourse
- smoking [5]

1.3.1 HPV

HPV DNA was detected in 74% of vaginal carcinomas and in 96% of VaIN 2/3 lesions. HPV 16 is the most commonly detected subtype both for VaIN and invasive tumors (59%).

1.3.3 VaIN

A vaginal intraepithelial neoplasia (VaIN) may be found sequentially or simultaneously with vaginal cancer. The precise incidence of VaIN is not clear. It is often reported as 0.2 to 0.3 cases per 100 000 women and year [6]. There is a coincidence with other neoplasias of the lower anogenital tract [7, 14]. The data show that long-term follow-up is necessary in all cases with VaIN. The rate of progression for VaIN developing into vaginal carcinoma is 2–5%. The same chapter in the long version of this guideline provides more details on the above data on the rate of progression.

2 Prevention and screening

2.1 Primary prevention

Consensus-based Statement 2.S4	
Expert consensus	Strength of consensus +++
Because of the heterogeneity of the data, it is not possible to provide a final statement on whether targeted sexual hygiene, which is recommended for other sexually transmissible diseases, has a preventative effect on vaginal neoplasia.	

Based on the distribution of HPV types, up to 60% of all vaginal carcinomas could theoretically be prevented by HPV vaccination [8]. According to the current recommendations of the STIKO, HPV vaccination is also useful with respect to the primary prevention of vaginal cancer and its precursors. As smoking increases the risk of women who test positive for HPV (high-risk types) developing a VaIN [9], women who smoke should always be provided with appropriate information in the context of preventing VaIN. The long version of this chapter includes details on the role of specific protective measures.

2.2 Screening (secondary prevention)

Consensus-based Statement 2.S5	
Expert consensus	Strength of consensus +++
The legally mandated screening program for cervical cancer offers the opportunity to diagnose vaginal cancers and their precursors at an early stage.	

3 Healthcare structures

3.2 Treatment in oncology centers

Consensus-based Recommendation 3.E1	
Expert consensus	Strength of consensus +++
Patients with vaginal cancer should be treated by an interdisciplinary, interprofessional team. The team should have access to all necessary medical specialties and occupations in a cross-sectoral network. A certified center is most likely to be able to provide this extensive access.	

3.2.2 Centers – interdisciplinary tumor board

Consensus-based Recommendation 3.E2	
Expert consensus	Strength of consensus +++
All patients with vaginal cancer must be presented to an interdisciplinary tumor board.	

4 Pathology

4.1 Classification of precancerous lesions (► Table 4)

► **Table 4** Nomenclature of HPV-associated precancerous vaginal lesions [10–12].

Description	Condylomatous lesion	Low-grade dysplasia	Intermediate-grade dysplasia	High-grade dysplasia	Carcinoma in situ
WHO (2003)	VaIN 1		VaIN 2	VaIN 3	
LAST project*	Low-grade squamous intraepithelial lesion (LSIL)		High-grade squamous intraepithelial lesion (HSIL)		
WHO (2014)	Low-grade squamous intraepithelial lesion (LSIL) syn.: VaIN 1		High-grade squamous intraepithelial lesion (HSIL) syn.: VaIN 2 and VaIN 3		

* LAST = Lower Anogenital Squamous Terminology Standardization project of the College of American Pathologists and the American Society of Colposcopy and Cervical Pathology [13].

4.2 Morphology of precancerous vaginal lesions

Consensus-based Recommendation 4.E3

Expert consensus	Strength of consensus +++
The clinical terminology and morphological workup of a precancerous vaginal lesion (vaginal intraepithelial neoplasia; VaIN) must be based on the most recent valid version of the WHO classification. In addition to its classification as LSIL or HSIL, HPV-associated changes (e.g. condylomas) should be specified and the lesion should be graded (VaIN 1 to 3).	

4.3 Vaginal Paget's disease

Consensus-based Recommendation 4.E4

Expert consensus	Strength of consensus +++
If histological examination detects pagetoid changes in a vaginal biopsy specimen, locoregional cancer and vulvar Paget's disease with vaginal involvement must be clinically excluded.	

4.4 Morphology of malignant vaginal tumors

4.4.1 Tumor typing

Consensus-based Recommendation 4.E5

Expert consensus	Strength of consensus +++
The histological classification of malignant vaginal tumors must be based on the most current version of the WHO classification.	

4.4.2 Staging of vaginal carcinoma

Postoperative staging is done using the pTNM classification system [14]; citing the FIGO stage [15] is optional (s. Chapter 5.7).

From a morphological standpoint, the WHO definition of vaginal cancer is problematic. According to this definition, squamous cell cancer of the vagina is defined as a vaginal carcinoma without a previous cervical or vulvar carcinoma in the 10 years before the current diagnosis [11,16,17]. Otherwise the vaginal cancer is

considered to be a recurrence of a previously treated carcinoma. Equally problematic is the statement by FIGO that squamous cell cancer of the vagina with involvement of the cervix should be classified as a cervical carcinoma [17].

As with cervical and vulvar carcinomas, the *depth of invasion* should be defined as the extent of stromal invasion measured from the epithelial-stromal border at the most superficial dermal papilla adjacent to invasion to the deepest point of invasion [13, 14, 18]. Lymph node infiltration which extends beyond the deepest point of invasion must not be included in the measured depth of invasion or the tumor thickness but must be classified as L1 [13, 14, 18]. *Tumor thickness* is measured from the surface of the tumor or, in the case of (strongly) keratinized squamous cell carcinomas, from the granular cell layer to the deepest point of invasion [13, 19].

4.4.4 Evaluation of tissue specimens

Consensus-based Recommendation 4.E6

Expert consensus	Strength of consensus +++
Biopsy specimens obtained from areas suspicious for VaIN must be processed and sliced into sections for further evaluation.	

4.4.4.1 Diagnostic biopsies

Consensus-based Recommendation 4.E7

Expert consensus	Strength of consensus +++
The biopsy findings report must provide information about the confirmation and type of VaIN, the presence of any dermatological disease, any virus-associated changes, and possible invasion.	

4.4.4.2 Specimens after local excision, colpectomy, hysterocolpectomy and lymph node status

Consensus-based Recommendation 4.E8	
Expert consensus	Strength of consensus +++
Morphological processing of colpectomy specimens in vaginal cancer must be carried out in such a way that all therapeutic and prognostically relevant parameters can be evaluated. The findings report must use the most recent valid WHO classification of tumor types and the most current TNM classification for staging.	

Consensus-based Recommendation 4.E9	
Expert consensus	Strength of consensus +++
The report detailing the histological findings of (radical) colpectomy specimens resected for vaginal cancer must include the following information: <ul style="list-style-type: none"> histological type using the WHO classification grading proof/absence of lymph node or vascular invasion (LN und V status) proof/absence of perineural infiltration (PNI status) staging (pTNM) depth of invasion in mm three-dimensional tumor size in cm minimum metric distance between the carcinoma and any associated VaIN measured from the edge of the resection to the VaIN minimum metric distance between the tumor and the soft-tissue edge of the resection (paracolpic tissue) R classification (UICC) 	

Consensus-based Recommendation 4.E10	
Expert consensus	Strength of consensus +++
All resected lymph nodes obtained by lymphadenectomy during the surgical treatment of vaginal cancer must be examined histologically.	

Consensus-based Recommendation 4.E11	
Expert consensus	Strength of consensus +++
Lymph nodes up to a diameter of approx. 0.3 cm should be entirely embedded; larger lymph nodes should be cut in half along their longitudinal axis and also completely embedded.	

According to the UICC and TNM classification systems, *micrometastasis* is defined as the histological confirmation of tumor cells measuring ≥ 0.2 mm and no larger than 0.2 cm in lymph nodes [20,21]. Tumor cells with a total length of <0.2 mm are defined as *isolated tumor cells* in lymph nodes [20,21]. The detection of isolated tumor cells and evidence of micrometastasis are not relevant for the staging of vaginal cancer.

Consensus-based Recommendation 4.E12	
Expert consensus	Strength of consensus +++
The report on the findings for lymphadenectomy specimens resected for vaginal cancer must include the following information: <ul style="list-style-type: none"> The number of affected lymph nodes compared to the number of resected lymph nodes together with information on the biopsy location and side (pelvic, poss. inguinofemoral) The size of the largest lymph node metastasis in mm Information whether lymph node metastasis has spread beyond the capsule or not Information on the presence/absence of isolated tumor cells in the lymph node, in lymphatic vessels in perinodal adipose tissue, and/or in the lymph node capsule 	

4.4.4.3 Sentinel lymph nodes

Consensus-based Recommendation 4.E13	
Expert consensus	Strength of consensus +++
In cases with vaginal cancer, the sentinel lymph nodes must be completely embedded and cut into slides for examination. Sentinel lymph nodes which are found to be negative based on an examination of their morphology using H&E staining, must additionally be investigated by immunohistochemistry (ultrastaging).	

4.4.5 Morphological prognostic factors

The prognostic contribution of individual morphological tumor characteristics is summarized in ► **Table 5**.

► **Table 5** Prognostic factors for vaginal cancer.

Name	Standard factor	Risk/prognostic factor	Relevant for treatment
Tumor stage	Yes	Yes	Yes
Lymph node status	Yes	Yes	Yes
Size of respective lymph node metastasis	Yes	Unclear	Yes
Number of inguinal lymph nodes with metastatic disease	Yes	Unclear	Yes
Extracapsular extension of inguinal lymph node metastasis	Yes	Unclear	Yes
Perineural infiltration (PNI status)	Yes	Unclear	No
Lymph node infiltration (LN status)	Yes	Unclear	No
Venous invasion (V status)	Yes	Unclear	No
Resection margins (residual tumor status; R classification)	Yes	Yes	Yes
Depth of invasion in mm	Yes	Unclear	No
Grading	Yes	Unclear	No
Three-dimensional tumor size in cm	Yes	Unclear	Yes

Continued next page

► **Table 5** Prognostic factors for vaginal cancer. (Continued)

Name	Standard factor	Risk/prognostic factor	Relevant for treatment
Location of the cancer in the vagina	Yes	Unclear	Yes (poss. surgical approach)
Macroscopic type of growth of the carcinoma	Yes	Unclear	No
Multifocal carcinoma	Yes	Unclear	Yes (surgical approach)
Peritumoral VaIN	Yes	Unclear	Yes (surgical approach)
Histological tumor type	Yes	Unclear	No (pure adenocarcinoma, poss. not radiosensitive)
HPV confirmation in the carcinoma	No	Unclear	No
Pattern of invasion	No	Unclear	No
Immunohistochemical ultrastaging of lymph nodes for metastasis	No	Unclear	Unclear
Molecular markers	No	Unclear	Unclear

5 Diagnostic workup

5.2 Clinical workup

Consensus-based Statement 5.S6

Expert consensus	Strength of consensus +++
The diagnostic workup of a suspicious vaginal lesion must consist of clinical, cytological and colposcopic examinations depending on the manifestation of the lesion. The lesion must be biopsied if the findings are suspicious.	

5.3 Histological workup

All suspicious lesions must be examined histologically.

5.4 Pretreatment staging of a carcinoma

Consensus-based Recommendation 5.E14

Expert consensus	Strength of consensus +++
Prior to treatment of a confirmed carcinoma, the following examinations must be carried out:	
<ul style="list-style-type: none"> gynecological examination of the entire anogenital area (multicentric/multifocal) determination of the location, spread and size of the tumor (colposcopy) assessment of the infiltration depth (palpation and poss. histological examination) assessment of spread to neighboring organs urethrocytoscopy, rectoscopy, poss. anal sonography depending on the location imaging examination depending on the clinical spread of the tumor 	

5.5 Diagnostic workup of advanced tumors

Because of the close proximity of neighboring organs and because surgical treatment often requires extensive excision to obtain healthy margins, the indications for exploration using endoscopy and imaging should be interpreted liberally.

For this reason, screening for distant metastasis in cases with large tumors must be done prior to starting treatment (see 5.6).

5.6 Imaging workup for vaginal cancer

5.6.1 Diagnostic workup of the primary tumor

Consensus-based Statement 5.S7

Expert consensus	Strength of consensus +++
Pelvic MRI is the imaging modality of choice for the local staging of histologically confirmed vaginal carcinoma from FIGO stage II onwards.	

Consensus-based Recommendation 5.E15

Expert consensus	Strength of consensus +++
The current recommendations (protocol) for gynecological pelvic tumors must be followed when carrying out a functional pelvic MRI to achieve the best possible diagnostic accuracy.	

Consensus-based Statement 5.S8

Expert consensus	Strength of consensus +++
The value of FDG-PET/CT for the staging of vaginal cancer has not been confirmed in the primary setting.	

5.6.2 Diagnostic workup of lymph nodes

Consensus-based Statement 5.S9

Expert consensus	Strength of consensus +++
The amount of information which can be obtained from imaging procedures to assess pelvic lymphatic drainage in cases with primary vaginal carcinoma is higher with functional MRI than with CT or standard MRI.	

5.6.3 Distant metastasis

Consensus-based Recommendation 5.E16

Expert consensus	Strength of consensus +++
For complete staging, a CT scan of the abdomen and chest using contrast medium should be carried out in cases with advanced vaginal carcinoma (≥ FIGO II) or if there is a reasonable suspicion of metastasis.	

Consensus-based Recommendation 5.E17

Expert consensus	Strength of consensus +++
Prior to any planned pelvic exenteration, PET/CT may be used in patients with primary vaginal cancer to exclude distant metastasis insofar as this is possible.	

5.6.4 Imaging in radiation therapy

Consensus-based Recommendation 5.E18	
Expert consensus	Strength of consensus +++
Patients who are treated with percutaneous radiotherapy, combined radiochemotherapy or brachytherapy must have an MRI scan at the start of planning treatment and to monitor therapy; where possible, the scan should be a functional MRI scan.	

5.6.5 Diagnostic workup for recurrence

Consensus-based Recommendation 5.E19	
Expert consensus	Strength of consensus +++
Patients with a suspicion of local recurrence of vaginal cancer should have a functional pelvic MRI scan to assess the extent of local spread in the pelvis.	

Consensus-based Recommendation 5.E20	
Expert consensus	Strength of consensus +++
Prior to planning treatment, PET/CT may be indicated in patients with a suspicion of extensive recurrence of vaginal carcinoma extending beyond the pelvic area.	

5.7 Staging

Staging is carried out using the FIGO and TNM classification systems (► **Table 6**). The findings at surgery together with the results of the histopathological examination of the surgical specimens will determine the staging.

The pelvic lymph nodes (obturator, internal iliac, external iliac and other unspecified pelvic LNs) are the regional lymph nodes for tumors in the upper two-thirds of the vagina. The inguinofemoral LNs are the regional LNs for tumors in the lower third of the vagina.

7 Treatment of vaginal intraepithelial neoplasia (VaIN)

7.1 Local surgical therapy

Consensus-based Statement 7.S10	
Expert consensus	Strength of consensus +++
Before starting any superficial treatment for VaIN, one or more biopsies must be carried out to exclude invasive carcinoma where possible. If there is a cytological suspicion of invasion, destructive therapy must not be carried out and treatment must consist of excision instead.	

► **Table 6** Vaginal cancer staging according to AJCC 2017 [22]/FIGO (2018) [15]/TNM 2017 [14].

UICC	FIGO	Tumor spread
TX		Primary tumor cannot be assessed due to lack of information
T0		No evidence of a primary tumor
Tis	¹⁾	Carcinoma in situ, vaginal intraepithelial neoplasia (VaIN) grade 3
T1a	I	Tumor is limited to the vagina and no larger than 2 cm, it has not spread (N0, M0)
T1b	I	Tumor is limited to the vagina and larger than 2 cm, it has not spread (N0, M0)
T2a	II	Tumor has infiltrated paravaginal tissue (paracolpium), is not larger than 2 cm, has not reached the pelvic wall, it has not spread (N0, M0)
T2b	II	Tumor has infiltrated paravaginal tissue (paracolpium), is larger than 2 cm but has not reached the pelvic wall, it has not spread (N0, M0)
T1 bis T3	III III	Tumor is growing into the pelvic wall and/or the lower third of the vagina and/or blocks the flow of urine, which is causing kidney problems
N1		Tumor has spread into regional pelvic or inguinal LNs, no distant metastasis
T3		Tumor is growing into the pelvic wall and/or the lower third of the vagina and/or blocks the flow of urine
N0		Tumor has not spread (N0, M0)
M0		
T4	IVA	Tumor has infiltrated the bladder mucosa and/or rectum and/or has spread beyond the pelvis ²⁾
Any N		Tumor may or may not have spread to regional LNs, no distant metastasis
M0		
Any T	IVB	Tumor has spread to distant organs (incl. pelvic LN metastasis), may or may not be infiltrating adjacent structures
Any N		Tumor may or may not have spread to regional LNs
M1		

¹⁾ The FIGO classification does not envisage a stage 0 (Tis).

²⁾ The presence of a bullous edema in the bladder mucosa is not enough to classify a tumor as T4.

► **Table 7** Treatment options for high-grade VaIN depending on the location of the lesion.

VaIN 2–3 (HSIL)	Lower third	Intermediate third	Vaginal vault	Entire vagina
HPV-induced	Excision, PE/laser vaporization, local drug therapy	Excision, PE/laser vaporization, local drug therapy	Excision, PE/laser vaporization, upper colpectomy	Skinning resection of vaginal epithelium, colpectomy, local drug therapy
HPV-negative	Excision	Excision	Excision, upper colpectomy	Colpectomy, skinning resection of vaginal epithelium

Consensus-based Recommendation 7.E21**Expert consensus** **Strength of consensus +++**

The decision which of the available guideline-based treatment options for VaIN to apply must be made on an individual basis.

► **Table 7** shows the optimal treatment approaches for high-grade VaIN according to their HPV status and vaginal location.

7.2 Local drug therapy

Local treatment may be used as an alternative to surgical treatment. This includes therapy with 5-FU or imiquimod (both are off-label uses). There are also reports of using brachytherapy.

The choice of treatment is based on the grade of the VaIN lesion (► **Table 8**).

► **Table 8** Recommendations for treatment according to VaIN grade.

VaIN 1 (condylomatous lesion) Low-grade squamous intraepithelial lesion LGSIL, flat condyloma	VaIN 2–3 High-grade intraepithelial neoplasia HGSIL
Regular monitoring, in exceptional cases destruction, excision, local application of imiquimod (off-label use)	Extensive PEs, followed by destruction or surgical removal (excision, skinning colpectomy, skinning excision, partial/total colpectomy) or radiotherapy

7.3 Recurrence and progression rates**Consensus-based Recommendation 7.E22****Expert consensus** **Strength of consensus +++**

Patients treated for VaIN must be offered regular follow-up examinations for the rest of their lives because the rate of recurrence for VaIN is high.

More information on the rates of recurrence and progression is available in the long version of the guideline.

8 Surgical treatment of invasive carcinoma

The majority of invasive vaginal cancers are treated with radio(chemo)therapy [8, 23–25]. Local surgical treatment ranges from local excision to partial or total colpectomy to anterior and/or posterior exenteration [26].

8.1 FIGO stage I**Consensus-based Statement 8.S11****Expert consensus** **Strength of consensus +++**

Surgery may be used to treat FIGO stage I vaginal carcinoma.

Consensus-based Recommendation 8.E23**Expert consensus** **Strength of consensus +++**

Circumscribed FIGO stage I tumors should be excised locally with tumor-free margins; the surgical treatment of larger tumors should consist of colpectomy or hysterectomy, if necessary.

8.2 FIGO stage II**Consensus-based Statement 8.S12****Expert consensus** **Strength of consensus +++**

Radio(chemo)therapy is the standard therapy for tumor stages II to IV. Exenteration to treat stage IV vaginal carcinoma is an individual therapy decision.

8.3 Stage III/IV

The standard therapy consists of radio(chemo)therapy. In cases with infiltration through the wall into adjacent organs (bladder and/or rectum), anterior and/or posterior exenteration with creation of a neobladder and/or a colostomy is a surgical option which has to be decided on in the context of an individual therapy decision.

8.4 Plastic reconstruction

Consensus-based Recommendation 8.E24	
Expert consensus	Strength of consensus +++
Before undergoing colectomy, the patient should be informed about the possibility of vaginal plastic reconstruction.	

9 Surgery of lymph drainage areas

9.1 Introduction

To date, sentinel lymph node imaging has not played any significant role in the diagnosis and treatment of vaginal cancer. The lack of information about lymphatic drainage in vaginal cancer is why lymphatic imaging with sentinel node analysis is necessary. The current practice of treating all regional lymph node stations either surgically or with radiotherapy is probably overtreatment and could be reduced in individual cases with targeted imaging and biopsies of sentinel lymph nodes.

9.2 Indication

The issue whether to lymph node (LN) staging should be carried out in cases with vaginal carcinoma or not is a question which affects both patients for whom primary surgery is indicated and patients for whom primary radio(chemo)therapy is indicated. If surgical examination of the lymph node areas is not possible or the patient does not want it, then primary radio(chemo)therapy is indicated and should potentially also include the site of the primary tumor (see Chapter 10).

9.3 Lymphatic drainage from the vagina

Consensus-based Statement 9.S13	
Expert consensus	Strength of consensus +++
Because the correlation between tumor location and the direction of lymphatic flow is not clear due to extensive lymphatic anastomosis in the vagina and lesser pelvis, it is not possible in individual cases to clearly link the vaginal tumor site with the direction of lymphatic flow.	

The literature on this issue is discussed in the long version of the guideline.

9.4 Vaginal cancer and risk of lymphatic metastasis

Consensus-based Statement 9.S14	
Expert consensus	Strength of consensus +++
There are no evidence-based parameters which show a close correlation between vaginal cancer and the risk of lymphatic metastasis. As with vulvar cancer, an infiltration depth of > 1 mm may be an indication of an incipient risk of lymphatic metastasis.	

9.5 Sentinel node procedures

9.5.1 Benefit of sentinel node procedures

Because of the lack of studies on the benefits of sentinel node procedures in vaginal cancer, the use of these procedures in vaginal cancer is still experimental. Studies of adjacent primary tumors of the uterine cervix and vulva provide some positive evidence for the use of sentinel node procedures in vaginal cancer. The flow chart in ► Fig. 1 shows the conventional and the experimental sequence for diagnosis and treatment; the sequence to be followed is described in Chapter 9.6.

9.5.2 Lymph node mapping using sentinel lymph node technique

Consensus-based Statement 9.S15	
Expert consensus	Strength of consensus +++
Sentinel lymph node mapping and tracing the lymphatic drainage pathway in cases with vaginal cancer is the precondition for carrying out SLNB and for planning any subsequent surgical and/or radiotherapeutic treatment.	

Consensus-based Recommendation 9.E25	
Expert consensus	Strength of consensus +++
The following preconditions must be adhered to when using the sentinel lymph node technique in cases with vaginal cancer:	
<ul style="list-style-type: none"> No clinically suspicious lymph nodes and/or nodes suspicious on imaging. The diameter of the primary tumor is no larger than 4 cm in the vaginal plane and the tumor has not infiltrated any structures beyond the vagina (FIGO I). The patient has not undergone any prior operations in the lymphatic drainage area to be treated. Imaging is done using ^{99m}technetium nanocolloid. A gamma probe must be used during surgical LN exploration; patent blue or – particularly when carrying out laparoscopic exploration – indocyanine green (ICG) may also be used for staining. All resected sentinel LNs negative on H&E staining are subjected to pathologic ultrastaging with immunohistochemistry. Those inguinal and pelvic lymphatic drainage areas not mapped using the sentinel LN technique are systematically explored surgically or included in the primary therapy (systematic LNE or RCTX). 	

9.5.3 Validity of sentinel lymph node biopsy

Consensus-based Recommendation 9.E26	
Expert consensus	Strength of consensus +++
The sentinel lymph node technique may be used if the patient has consented after being informed in detail about the limited validity of the method in vaginal cancer because of the current lack of data.

► **Fig. 1** Flowchart for the diagnostic workup and treatment of vaginal carcinoma with the option of carrying out a sentinel LN procedure or not. [rerif]

Consensus-based Statement 9.S16

Expert consensus

Strength of consensus +++

Because of the rarity of these tumors, no valid data on the diagnostic certainty of SLNB in vaginal cancer will be available in the foreseeable future.

Systematic inguino-femoral or pelvic lymphadenectomy or radio (chemo)therapy of the respective areas probably offers greater oncological safety but patients will have to accept a higher rate of side effects.

To evaluate the usefulness of sentinel lymph node biopsy in vaginal cancer, a new central register has been set up to collect treatment data and the course of disease of all patients with vagi-

nal cancer in Germany (“knowledge-generating healthcare research” by the DKG). This national interdisciplinary vaginal carcinoma register is supported by the medical societies DGGG, AGO and DEGRO. All cases of vaginal cancer must be reported to the Radiotherapy Department of Cologne University (email: martina.illig@uk-koeln.de). All hospitals with a tumor board which discusses and treats cases of vaginal carcinoma are requested to contact the registration office.

9.5.5 Planning primary radio(chemo)therapy

Consensus-based Recommendation 9.E27	
Expert consensus	Strength of consensus +++
If SLN imaging is carried out preoperatively followed by intraoperative SLN biopsy, the findings should be taken into consideration when planning the radiation fields for primary radiotherapy.	

Please refer to this chapter in the long version of the guideline to read how staging results from sentinel lymph node procedures can improve the situation.

9.6 Diagnosis and therapy with and without sentinel lymph node procedures

9.6.1 Process description of diagnostic workup and treatment

This chapter describes the recommended treatment approach for primary vaginal carcinoma with and without a sentinel lymph node procedure; the circled numbers correspond to the respective steps shown in ► Fig. 1.

9.7 Systematic lymphadenectomy

Lymphatic drainage areas relevant for vaginal cancer include the pelvic, anorectal and inguinofemoral lymph nodes. In addition to these LNs, very advanced lymphogenic metastatic vaginal cancer may also affect the paraaortic LNs. As with SLN procedures, pretherapeutic systematic LNE in the above-mentioned lymphatic drainage areas may be useful to determine the extent of the required radiation for subsequent primary radio(chemo)therapy based on staging findings. Lymph node regions shown to have no metastatic involvement should not be irradiated.

If metastatic involvement is found to be present in pelvic lymph nodes on one side, it is important to ensure that both sides are treated with radiotherapy in accordance with the uniform approach used to treat pelvic lymph node metastasis from other primary tumors (carcinomas of the uterine cervix, prostate, endometrium, rectum, and anus). There are no data available on hemipelvis radiotherapy for vaginal cancer.

9.8 Surgical tumor reduction (debulking) prior to radio(chemo)therapy

In cases with advanced vaginal carcinoma and large circumscribed lymph node metastases in the groin or pelvis, the option to carry out preparatory surgical debulking as a means of improving the response to radio(chemo)therapy should be considered. The overall oncological situation, the patient’s general operability, and lo-

cal resectability as well as the expected morbidity following therapy must all be taken into consideration.

Consensus-based Recommendation 9.E28	
Expert consensus	Strength of consensus +++
Treatment planning for vaginal carcinoma should be based on the flow-chart showing the diagnostic workup and treatment of vaginal carcinoma (► Fig. 1).	

10 Radio(chemo)therapy for vaginal carcinoma

10.1 Introduction

Radiotherapy alone has been used since many decades to treat both local and advanced squamous cell carcinoma and adenocarcinoma of the vagina.

Depending on the tumor stage, radiotherapy alone can achieve high local control rates, ranging from 85–95% for FIGO stage I, to 70–80% for FIGO stage II and around 50–70% for FIGO stages III–IVA [27–31].

Please refer to this chapter in the long version of the guideline for details on the dose-response relationship, the different radiotherapy techniques and the target volume definitions.

10.5 Radiotherapy of the tumor region

A second resection should be considered if the tumor was not resected in its entirety. If this is not feasible or if the expected functional results of this second resection are expected to be unsatisfactory, then local radiotherapy should be administered to improve local control.

Consensus-based Recommendation 10.E29	
Expert consensus	Strength of consensus +++
In primary radio(chemo)therapy, the target volume should cover the primary tumor including the safety margin with a dose of > 70 Gy.	

Consensus-based Statement 10.S17	
Expert consensus	Strength of consensus +++
There is no evidence which specifies a minimal histological safety margin between the tumor and the edge of the resected specimen nor that resection margins below such a minimal histological safety margin represent an indication for administering radiotherapy to the tumor region postoperatively.	

Consensus-based Recommendation 10.E30	
Expert consensus	Strength of consensus +++
Postoperative radiotherapy of the tumor region must be recommended after R1 and R2 resection if a second resection is not feasible.	

10.6 Radiotherapy of the lymphatic drainage pathways

10.6.1 Inguinal lymph nodes

If inguinal lymph node metastasis has been confirmed histologically, the recommendations to administer postoperative radiotherapy will be based on the recommendations used to treat vulvar cancer. Radiotherapy planning should opt for modern proton therapy in preference to electron therapy.

10.6.2 Pelvic lymph nodes

Radiotherapy with bilateral radiation of the pelvic lymph drainage pathways is recommended if pelvic lymph node metastasis has been confirmed histologically. Even if metastasis is only confirmed on one side, radiotherapy should always be administered to both sides.

10.7 Radio(chemo)therapy

Consensus-based Recommendation 10.E31

Expert consensus	Strength of consensus +++
Primary radiotherapy should also be offered in the form of simultaneous radiochemotherapy.	

Consensus-based Recommendation 10.E32

Expert consensus	Strength of consensus +++
The inguinofemoral and pelvic lymphatic drainage areas on both sides should also be irradiated if surgical lymph node staging was indicated but surgical staging was not carried out.	

Consensus-based Recommendation 10.E33

Expert consensus	Strength of consensus +++
The patient's comorbidities, own wishes, and clinical situation need to be considered before administering cisplatin ± 5-FU or mitomycin ± 5-FU.	

Consensus-based Statement 10.S18

Expert consensus	Strength of consensus +++
In primary radiotherapy, achieving sufficiently high tumor doses is decisive for the success of therapy. Brachytherapy, possibly in combination with percutaneous radiotherapy, plays an important role in this context.	

Consensus-based Recommendation 10.E34

Expert consensus	Strength of consensus +++
As with vulvar cancer, adjuvant radio(chemo)therapy after R1/R2 resection should be administered to the tumor area and the affected groin area if inguinal metastasis is present and bilaterally if there is pelvic metastasis.	

The recommendation to administer simultaneous radiochemotherapy to treat vaginal cancer is a transfer of the experience with this approach in other tumors. Because of the rarity of vaginal carcinoma, we recommend that vaginal cancer should be treated in centers which deal with larger numbers of patients [32–34].

10.9 Side effects of therapy, their prophylaxis and treatment

10.9.2 Late radiogenic side effects

Please refer to this chapter in the long version of the guideline for details on therapy-related toxicity, the choice of radiation technique and its impact on toxicity.

Symptomatic measures such as treatment for diarrhea, sitz baths, vaginal douching and the intravaginal application of a topical ointment (poss. using a tampon) to prevent adhesions are useful. Acute reactions are common but usually heal after the end of radiotherapy with no further effects. Important prophylactic measures against chronic consequences of scarring such as vaginal stenosis include the above-listed therapies applied consistently to treat acute reactions and the early and regular use of vaginal dilators, particularly in young and sexually active patients [35–37, 38].

10.9.3 Preservation of ovarian function and/or fertility

Young patients should be informed about the possibility of preserving ovarian function using ovariopexy with clip marking and the use of the latest radio-oncology techniques [39–43]. Please consult the German-language AWMF S2k guideline “Fertilitätserhalt bei onkologischen Erkrankungen” on preserving fertility in patients with oncologic disease for more information about indications and techniques [44].

11 Systemic therapy

The current data on the use of systemic therapy to treat vaginal cancer is based on single case reports and small series which were analyzed retrospectively. Most therapeutic concepts were adapted from the treatment concepts used for cervical cancer.

11.2 Neoadjuvant chemotherapy

Consensus-based Statement 11.S19

Expert consensus	Strength of consensus +++
The use of neoadjuvant chemotherapy to treat vaginal cancer is currently still an experimental concept.	

11.3 Radio(chemo)therapy

Consensus-based Statement 11.S20

Expert consensus	Strength of consensus +++
Using radio(chemo)therapy to treat vaginal cancer is analogous to using radio(chemo)therapy to treat cervical and vulvar cancer.	

11.4 Chemotherapy in the palliative setting (recurrence, secondary metastasis, primary metastasizing vaginal carcinoma)

The references for the few available reports and studies on vaginal cancer are given in the long version of the guideline.

For the general chapters **12 Supportive Therapy**, **13 Psycho-oncology and Quality of Life**, **14 Rehabilitation** and **15 Integrative Medicine**, please refer to the long version of the guideline on the homepage of the AWMF: <https://www.awmf.org/leitlinien/detail/II/032-042.html>

16 Follow-up

Consensus-based Recommendation 16.E35	
Expert consensus	Strength of consensus +++
Patients who were treated for vaginal HSIL should have regular risk-adapted follow-up appointments for the rest of their lives.	

Consensus-based Recommendation 16.E36			
Expert consensus		Strength of consensus +++	
Follow-up care of vaginal cancer should include the following routine examinations:			
Examination	1st–3rd year	4th–5th year	From 6th year
Medical history	every 3 months	every 6 months	annually
Clinical examination	every 3 months	every 6 months	annually
Speculum examination, colposcopy (cervix/vagina/ vulva/anus), cytology	every 3 months	every 6 months	annually
References: Adapted from Salani R et al. 2011 [45], Dannecker C et al. 2016 [46], Oonk MH et al. 2003 [47]			

The long version of this guideline includes additional information on the clinical follow-up, the short and long-term impact of the disease and its therapy, and the effects of lifestyle choices and psychosexual and psychosocial follow-up care.

17 Therapy for locoregional recurrence and distant metastasis

Around 90% of recurrences occur within the first five years [8, 48, 49]. About 25% of all recurrences are local or locoregional [48].

A palliative concept is used to treat distant metastasis; it is important to exclude any distant metastasis before deciding on the appropriate therapy to treat locoregional recurrence.

17.1 Diagnostic workup

The following diagnostic workup should be carried out if there is a suspicion of locoregional recurrence:

- gynecological examination and histological examination
- vaginal ultrasound imaging
- pelvic MRI [48]
- cystoscopy and rectoscopy, exclusion of fistula
- CT scan of the thorax and abdomen to exclude distant metastasis

It should be noted in this context that it is not uncommon for primary therapy to create long-term complications which can mimic recurrence, particularly fistula formation [49].

17.2 Treatment of locoregional recurrence

Consensus-based Statement 17.S21	
Expert consensus	Strength of consensus +++
The decision to treat local or locoregional recurrence depends on the previous therapy, the extent of recurrence, and the patient's general condition. The decision is made on an individual basis; treatment options include surgery, radiotherapy, radio(chemo)therapy and best supportive care.	

Consensus-based Recommendation 17.E37	
Expert consensus	Strength of consensus +++
The decision about the appropriate treatment approach for a patient with local or locoregional recurrence must be made by an interdisciplinary tumor board.	

The long version of the guideline has drafted some cornerstones for treating recurrence which must be followed. The limited options to treat distant metastasis are explained in the long version.

To read the general chapter **18 Palliative Medical Care**, please refer to the long version on the homepage of the AWMF: <https://www.awmf.org/leitlinien/detail/II/032-042.html>

Conflict of Interest

The conflicts of interests of the authors are listed in the long version of the guideline.

References

- [1] Schubert-Fritschle G, Schlesinger-Raab A, Engel J. Malignome der Vulva und Vagina. In: Dannecker C, Kolben M, Kürzl R, Hrsg. *Manuale Tumorzentrums München*. 2. Aufl. München: Zuckschwerdt Verlag; 2011
- [2] Lilic V, Lilic G, Filipovic S et al. Primary carcinoma of the vagina. *J BUON* 2010; 15: 241–247
- [3] Melnick S, Cole P, Anderson D et al. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. *N Engl J Med* 1987; 316: 514–516
- [4] Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ, eds. *SEER Survival Monograph: Cancer Survival among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics*. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD: NIH; 2007
- [5] Madsen BS, Jensen HL, van den Brule AJ et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina—population-based case-control study in Denmark. *Int J Cancer* 2008; 122: 2827–2834
- [6] Henson D, Tarone R. An epidemiologic study of cancer of the cervix, vagina, and vulva based on the Third National Cancer Survey in the United States. *Am J Obstet Gynecol* 1977; 129: 525–532
- [7] Aho M, Vesterinen E, Meyer B et al. Natural history of vaginal intraepithelial neoplasia. *Cancer* 1991; 68: 195–197
- [8] Gadducci A, Fabrini MG, Lanfredini N et al. Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors. *Crit Rev Oncol Hematol* 2015; 93: 211–224
- [9] Strander B, Andersson-Ellstrom A, Milsom I et al. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. *BMJ* 2007; 335: 1077
- [10] Horn LC, Schierle K. Pathologie der Präkanzerosen und der Karzinome von Vulva und Vagina sowie morphologische Prognosefaktoren. *Onkologie* 2009; 15: 15–27
- [11] Ferenczy AS, Colgan TJ, Herrington CS, Hirschowitz L, Löning T, Park KJ, Stoler M, Wells M, Wilbur DC, Wright T. Epithelial Tumors of the Vagina. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. *WHO Classification of Tumours of the female reproductive Tract*. Lyon: IARC Press; 2014: 210–217
- [12] Horn LC, Schierle K, Schmidt D et al. [Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed müllerian tumors. Facts and background]. *Pathologie* 2011; 32: 239–243
- [13] Darragh TM, Colgan TJ, Thomas Cox J et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. *Int J Gynecol Pathol* 2013; 32: 76–115
- [14] Wittekind C. *TNM-Klassifikation maligner Tumoren*. 8th ed. Weinheim: Wiley-VHC; 2017: 213–215
- [15] Adams TS, Cuello MA. Cancer of the vagina. *Int J Gynaecol Obstet* 2018; 143 (Suppl. 2): 14–21
- [16] Wu X, Matanoski G, Chen VW et al. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. *Cancer* 2008; 113: 2873–2882
- [17] Kurman RJ, Ronnett BM, Sherman ME, Wilkinson EJ. Tumors of the Vagina. Tumors of the Cervix, Vagina and Vulva. In: Kurman RJ, Ronnett BM, Sherman ME, Wilkinson EJ, eds. *AFIP Atlas of Tumor Pathology, Series 4*. Silver Spring: ARP Press; 2010: 255–291
- [18] Wilkinson EJ, Rico MJ, Pierson KK. Microinvasive carcinoma of the vulva. *Int J Gynecol Pathol* 1982; 1: 29–39
- [19] Crum CP, Herrington CS, McCluggage WG, Regauer S, Wilkinson EJ. Epithelial Tumors of the Vulva. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. *WHO Classification of Tumours of the female reproductive Tract*. Lyon: IARC Press; 2014: 233–242
- [20] Hermanek P, Hutter RV, Sobin LH et al. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. *Cancer* 1999; 86: 2668–2673
- [21] Wittekind C, Compton C, Brirley J, Sobin L. *TNM Supplement: a Commentary on Uniform Use*. London: Wiley-Blackwell; 2012
- [22] American Joint Committee on Cancer. Vagina. In: Amin MB, Edge S, Greene F et al., eds. *AJCC Cancer Staging Manual*. 8th ed. New York: Springer; 2017: 641–647
- [23] Luo LM, Huang HF, Pan LY et al. [Clinical analysis of 42 cases of primary malignant tumor in vagina]. *Zhonghua Fu Chan Ke Za Zhi* 2008; 43: 923–927
- [24] Stock RG, Chen AS, Seski J. A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. *Gynecol Oncol* 1995; 56: 45–52
- [25] Manetta A, Gutrecht EL, Berman ML et al. Primary invasive carcinoma of the vagina. *Obstet Gynecol* 1990; 76: 639–642
- [26] Tjalma WA, Monaghan JM, de Barros Lopes A et al. The role of surgery in invasive squamous carcinoma of the vagina. *Gynecol Oncol* 2001; 81: 360–365
- [27] Frank SJ, Jhingran A, Levenback C et al. Definitive radiation therapy for squamous cell carcinoma of the vagina. *Int J Radiat Oncol Biol Phys* 2005; 62: 138–147
- [28] de Crevoisier R, Sanfilippo N, Gerbaulet A et al. Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. *Radiother Oncol* 2007; 85: 362–370
- [29] Greenwalt JC, Amdur RJ, Morris CG et al. Outcomes of Definitive Radiation Therapy for Primary Vaginal Carcinoma. *Am J Clin Oncol* 2015; 38: 583–587
- [30] Lian J, Dundas G, Carlone M et al. Twenty-year review of radiotherapy for vaginal cancer: an institutional experience. *Gynecol Oncol* 2008; 111: 298–306
- [31] Jang WI, Wu HG, Ha SW et al. Definitive radiotherapy for treatment of primary vaginal cancer: effectiveness and prognostic factors. *Int J Gynecol Cancer* 2012; 22: 521–527
- [32] Smith GL, Jiang J, Giordano SH et al. Trends in the Quality of Treatment for Patients With Intact Cervical Cancer in the United States, 1999 Through 2011. *Int J Radiat Oncol* 2015; 92: 260–267
- [33] Showalter TN, Camacho F, Cantrell LA et al. Determinants of Quality Care and Mortality for Patients With Locally Advanced Cervical Cancer in Virginia. *Medicine (Baltimore)* 2016; 95: e2913
- [34] Lin JF, Berger JL, Krivak TC et al. Impact of facility volume on therapy and survival for locally advanced cervical cancer. *Gynecol Oncol* 2014; 132: 416–422
- [35] Bakker RM, ter Kuile MM, Vermeer WM et al. Sexual rehabilitation after pelvic radiotherapy and vaginal dilator use: consensus using the Delphi method. *Int J Gynecol Cancer* 2014; 24: 1499–1506
- [36] Bakker RM, Mens JW, de Groot HE et al. A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer. *Support Care Cancer* 2016. doi:10.1007/s00520-016-3453-2
- [37] Bakker RM, Vermeer WM, Creutzberg CL et al. Qualitative accounts of patients' determinants of vaginal dilator use after pelvic radiotherapy. *J Sex Med* 2015; 12: 764–773
- [38] Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev* 2016; (8): CD001500. doi:10.1002/14651858.CD001500.pub3
- [39] Perri T, Ben-Baruch G, Davidson T et al. Use of Titanium Spiral Tacks for Long-term Oophoropexy Before Pelvic Irradiation. *Int J Gynecol Cancer* 2014; 24: 1133–1136
- [40] Han SS, Kim YH, Lee SH et al. Underuse of ovarian transposition in reproductive-aged cancer patients treated by primary or adjuvant pelvic irradiation. *J Obstet Gynaecol Res* 2011; 37: 825–829

- [41] Morice P, Castaigne D, Haie-Meder C et al. Laparoscopic ovarian transposition for pelvic malignancies: indications and functional outcomes. *Fertil Steril* 1998; 70: 956–960
- [42] Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. *Hum Reprod Update* 2001; 7: 535–543
- [43] Ghadjar P, Budach V, Kohler C et al. Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation. *Radiat Oncol* 2015; 10: 50
- [44] DGGG; DGU; BGRM. Fertility preservation for patients with malignant disease. Guideline of the DGGG, DRU and BGRM (S2k – Level, AWMF Registry No.015/082, November 2017). 2017. Online: <http://www.ammf.org/leitlinien/detail/II/015-082.html>; last access: 15.02.2018
- [45] Salani R, Backes FJ, Fung MF et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. *Am J Obstet Gynecol* 2011; 204: 466–478
- [46] Dannecker C, Strand V, Hegewisch-Becker S. Nachsorge beim Vulva- und Vaginalkarzinom. *Der Onkologe* 2014; 20: 355–357
- [47] Oonk MH, de Hullu JA, Hollema H et al. The value of routine follow-up in patients treated for carcinoma of the vulva. *Cancer* 2003; 98: 2624–2629
- [48] Gardner CS, Sunil J, Klopp AH et al. Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. *Br J Radiol* 2015; 88: 20150033
- [49] Gunderson CC, Nugent EK, Yunker AC et al. Vaginal cancer: the experience from 2 large academic centers during a 15-year period. *J Low Genit Tract Dis* 2013; 17: 409–413

Guideline Program

Editors

Leading Professional Medical Associations

**German Society of Gynecology and Obstetrics
(Deutsche Gesellschaft für Gynäkologie
und Geburtshilfe e. V. [DGGG])**

Head Office of DGGG and Professional Societies
Hausvogteiplatz 12, DE-10117 Berlin
info@dggg.de
<http://www.dggg.de/>

President of DGGG

Prof. Dr. med. Anton Scharl
Direktor der Frauenkliniken
Klinikum St. Marien Amberg
Mariahilfbergweg 7, DE-92224 Amberg
Kliniken Nordoberpfalz AG
Söllnerstraße 16, DE-92637 Weiden

DGGG Guidelines Representatives

Prof. Dr. med. Matthias W. Beckmann
Universitätsklinikum Erlangen, Frauenklinik
Universitätsstraße 21–23, DE-91054 Erlangen

Prof. Dr. med. Erich-Franz Solomayer
Universitätsklinikum des Saarlandes
Geburtshilfe und Reproduktionsmedizin
Kirrberger Straße, Gebäude 9, DE-66421 Homburg

Guidelines Coordination

Dr. med. Paul Gaß, Dr. med. Gregor Olmes, Christina Meixner
Universitätsklinikum Erlangen, Frauenklinik
Universitätsstraße 21–23, DE-91054 Erlangen
fk-dggg-leitlinien@uk-erlangen.de
<http://www.dggg.de/leitlinienstellungnahmen>

**Austrian Society of Gynecology and Obstetrics
(Österreichische Gesellschaft für Gynäkologie
und Geburtshilfe [OEGGG])**

Frankgasse 8, AT-1090 Wien
stephanie.leutgeb@oeggg.at
<http://www.oeggg.at>

President of OEGGG

Prof. Dr. med. Petra Kohlberger
Universitätsklinik für Frauenheilkunde Wien
Währinger Gürtel 18–20, AT-1090 Wien

OEGGG Guidelines Representatives

Prof. Dr. med. Karl Tamussino
Universitätsklinik für Frauenheilkunde und Geburtshilfe Graz
Auenbruggerplatz 14, AT-8036 Graz

Prof. Dr. med. Hanns Helmer
Universitätsklinik für Frauenheilkunde Wien
Währinger Gürtel 18–20, AT-1090 Wien

**Swiss Society of Gynecology and Obstetrics
(Schweizerische Gesellschaft für Gynäkologie
und Geburtshilfe [SGGG])**

Gynécologie Suisse SGGG
Altenbergstraße 29, Postfach 6, CH-3000 Bern 8
sekretariat@sggg.ch
<http://www.sggg.ch/>

President of SGGG

Dr. med. Irène Dingeldein
Längmatt 32, CH-3280 Murten

SGGG Guidelines Representatives

Prof. Dr. med. Daniel Surbek
Universitätsklinik für Frauenheilkunde
Geburtshilfe und fetomaternal Medizin
Inselspital Bern
Effingerstraße 102, CH-3010 Bern

Prof. Dr. med. René Hornung
Kantonsspital St. Gallen, Frauenklinik
Rorschacher Straße 95, CH-9007 St. Gallen